RE:RE:RE:RE:Employee optionsGood point wittmann!
Yes, we need to deliver revenues.
So, we need to prove that future revenues are not a sci-fy story.
Of course, I'm not expecting to see the plasminogen being rocket fuel within a few months after the approval.
However, it will bring good revenues probably starting in mid 2018, and show the viability of the PPPS.
Also, it's important to keep on track for the IVIG trial. There again, even if this won't be an instant impact on revenues, it will show that the revenues growth is on the way.
Can we be in black ink in 2019? I think we will be getting closer to it.
The strategy of pursuing orphan drugs is about to pay.